Egyéves növekedési hormon pótló kezelés hatása növekedési hormon hiányos felnóttek szérumbeli tumormarkerszintjeire.

Translated title of the contribution: Serum tumor marker levels during a 12-months growth hormone replacement therapy in patients with adult growth hormone deficiency

Erika Hubina, László Kovács, István Szabolcs, Eva Rimanóczy, Sándor Czirják, Miklós Góth

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

INTRODUCTION: High growth hormone/insulin-like growth factor-1 level may have oncogenic potential in animal experiments, and in patients with acromegaly. There are also some data suggesting the development of different neoplasms in animals after growth hormone administration and in humans upon growth hormone replacement therapy. AIMS: The general opinion is however, that growth hormone replacement therapy has no oncogenic effect, but the tumor marker levels have not been studied so far. PATIENTS/METHODS: Nine patients participated in the study: 3 women, 6 men, aged between 21-52 years. 6 of them had multiple pituitary hormone deficiency and were on replacement therapy (thyroxine: 2, cortisone: 1, sexual steroids: 6 and desmopressin: 2 patients). The cause of growth hormone deficiency was the removal of pituitary tumor (6 patients) or craniopharyngioma (2 patients), and in 1 case the deficiency was idiopathic. The mean dose of growth hormone was 0.53 in female and 0.51 mg/day in male patients. Insulin-like growth factor-1, carcinoembryonal antigen, human choriogonadotropin hormone, alpha-fetoprotein, prostate specific antigen, tissue polypeptide antigen-M, ferritin, gastrointestinal carcinoma antigen, ovarian antigen, breast specific antigen, carcinoma antigen 50 were measured at baseline and after 3, 6 and 12 months of GH replacement. RESULTS: Insulin-like growth factor-1 standard deviation score increased: baseline: -4.1 +/- 0.5; 3 months: -0.3 +/- 0.3; 6 months: 0.7 +/- 0.2; 12 months: -0.2 +/- 0.6, P < 0.001 vs. baseline. The mean value of all tumor markers remained within the normal range and there was no significant increase within the normal range either. CONCLUSION: The lack of increase of tumor marker levels does not indicate possible oncogenic effect of one-year GH treatment in hypopituitary adults. The authors can not draw any far-reaching conclusions because of the low patient number and the short follow-up, but the measurement of tumor marker levels may provide useful means to follow up long-term therapy and for the early diagnosis of possible occult malignancy.

Translated title of the contributionSerum tumor marker levels during a 12-months growth hormone replacement therapy in patients with adult growth hormone deficiency
Original languageHungarian
Pages (from-to)601-605
Number of pages5
JournalOrvosi hetilap
Volume143
Issue number12
Publication statusPublished - Mar 24 2002

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Serum tumor marker levels during a 12-months growth hormone replacement therapy in patients with adult growth hormone deficiency'. Together they form a unique fingerprint.

  • Cite this